These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 29933033)

  • 1. Progress and challenges of selective Farnesoid X Receptor modulation.
    Massafra V; Pellicciari R; Gioiello A; van Mil SWC
    Pharmacol Ther; 2018 Nov; 191():162-177. PubMed ID: 29933033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting farnesoid X receptor for liver and metabolic disorders.
    Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
    Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesoid X receptor: from medicinal chemistry to clinical applications.
    Fiorucci S; Mencarelli A; Distrutti E; Zampella A
    Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesoid X receptor: A "homeostat" for hepatic nutrient metabolism.
    Massafra V; van Mil SWC
    Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):45-59. PubMed ID: 28986309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
    Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
    Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease.
    van Zutphen T; Bertolini A; de Vries HD; Bloks VW; de Boer JF; Jonker JW; Kuipers F
    Handb Exp Pharmacol; 2019; 256():207-234. PubMed ID: 31236687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patented Farnesoid X receptor modulators: a review (2019 - present).
    Gioiello A; Rosatelli E; Cerra B
    Expert Opin Ther Pat; 2024 Jul; 34(7):547-564. PubMed ID: 38308658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesoid X receptor modulators 2014-present: a patent review.
    Sepe V; Distrutti E; Fiorucci S; Zampella A
    Expert Opin Ther Pat; 2018 May; 28(5):351-364. PubMed ID: 29649907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
    Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
    Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FXR: a promising target for the metabolic syndrome?
    Cariou B; Staels B
    Trends Pharmacol Sci; 2007 May; 28(5):236-43. PubMed ID: 17412431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MECHANISMS IN ENDOCRINOLOGY: FXR signalling: a novel target in metabolic diseases.
    Sonne DP
    Eur J Endocrinol; 2021 May; 184(5):R193-R205. PubMed ID: 33630750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesoid X receptor modulators (2011 - 2014): a patent review.
    Sepe V; Distrutti E; Fiorucci S; Zampella A
    Expert Opin Ther Pat; 2015; 25(8):885-96. PubMed ID: 26183029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis.
    Cariou B
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):685-91. PubMed ID: 19195631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesoid X receptor: a potential therapeutic target in multiple organs.
    Zhang C; Wang Z; Feng Q; Chen WD; Wang YD
    Histol Histopathol; 2020 Dec; 35(12):1403-1414. PubMed ID: 33393073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
    Ho PP; Steinman L
    Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bile acid derivatives as ligands of the farnesoid x receptor: molecular determinants for bile acid binding and receptor modulation.
    Gioiello A; Cerra B; Mostarda S; Guercini C; Pellicciari R; Macchiarulo A
    Curr Top Med Chem; 2014; 14(19):2159-74. PubMed ID: 25388535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developments in bile salt based therapies: A critical overview.
    Donkers JM; Roscam Abbing RLP; van de Graaf SFJ
    Biochem Pharmacol; 2019 Mar; 161():1-13. PubMed ID: 30582898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease.
    Halilbasic E; Fuchs C; Traussnigg S; Trauner M
    Dig Dis; 2016; 34(5):580-8. PubMed ID: 27332721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting FXR in cholestasis: hype or hope.
    Fiorucci S; Distrutti E; Ricci P; Giuliano V; Donini A; Baldelli F
    Expert Opin Ther Targets; 2014 Dec; 18(12):1449-59. PubMed ID: 25200104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders.
    Fiorucci S; Mencarelli A; Palladino G; Cipriani S
    Trends Pharmacol Sci; 2009 Nov; 30(11):570-80. PubMed ID: 19758712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.